Frontline mTNBC: How to Choose Between These Two ADCs

For PD-L1–negative disease, two frontline ADCs may soon be available — giving clinicians real choice for the first time.

Dr. Hamilton discusses the key factors—response rate, side-effect profiles, and patient burden—that drive the sequencing decision in metastatic TNBC.